The estimated Net Worth of Gary Goldenberg is at least $1.08 Milion dollars as of 26 August 2024. Dr Goldenberg owns over 13,489 units of Verrica Pharmaceuticals Inc stock worth over $180,039 and over the last 6 years he sold VRCA stock worth over $330,510. In addition, he makes $571,573 as Chief Medical Officer at Verrica Pharmaceuticals Inc.
Sign up
Dr D VRCA stock SEC Form 4 insiders trading
Dr has made over 5 trades of the Verrica Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 13,489 units of VRCA stock worth $35,206 on 26 August 2024.
The largest trade he's ever made was selling 28,699 units of Verrica Pharmaceuticals Inc stock on 21 July 2023 worth over $138,616. On average, Dr trades about 6,668 units every 56 days since 2018. As of 26 August 2024 he still owns at least 94,261 units of Verrica Pharmaceuticals Inc stock.
You can see the complete history of Dr Goldenberg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Gary Goldenberg M.D. biography
Dr. Gary Goldenberg M.D. is the Chief Medical Officer at Verrica Pharmaceuticals Inc.
What is the salary of Dr D?
As the Chief Medical Officer of Verrica Pharmaceuticals Inc, the total compensation of Dr D at Verrica Pharmaceuticals Inc is $571,573. There are 4 executives at Verrica Pharmaceuticals Inc getting paid more, with Ted White having the highest compensation of $1,441,190.
How old is Dr D?
Dr D is 44, he's been the Chief Medical Officer of Verrica Pharmaceuticals Inc since . There are 13 older and 1 younger executives at Verrica Pharmaceuticals Inc. The oldest executive at Verrica Pharmaceuticals Inc is Lawrence Eichenfield, 62, who is the Director.
What's Dr D's mailing address?
Gary's mailing address filed with the SEC is C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER, PA, 19380.
Insiders trading at Verrica Pharmaceuticals Inc
Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning a John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.
What does Verrica Pharmaceuticals Inc do?
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
What does Verrica Pharmaceuticals Inc's logo look like?
Complete history of Dr Goldenberg stock trades at Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc executives and stock owners
Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Ted White,
President, Chief Executive Officer, Director -
Brian Davis,
Chief Financial Officer -
Joe Bonaccorso,
Chief Commercial Officer -
Ted White,
Pres, CEO & Director -
Dr. Gary Goldenberg M.D.,
Chief Medical Officer -
Mark Prygocki,
Independent Director -
Gary Goldenberg,
Chief Medical Officer -
Craig Ballaron,
Independent Director -
Sean Stalfort,
Director -
Diem Nguyen,
Director -
Lawrence Eichenfield,
Director -
Bradley Catalone,
Head of Drug Development -
Patrick Burnett,
Chief Medical Officer -
Christopher Hayes,
General Counsel, Corporate Secretary, Chief Legal Officer -
Paul Manning,
Chairman of the Board -
Dr. Bradley J. Catalone MBA, Ph.D.,
Head of Drug Devel. -
Eugene Scavola,
Exec. VP of Technical Operations -
Joe Bonaccorso,
Chief Commercial Officer -
Christopher G. Hayes,
Chief Legal Officer, Sec. & Gen. Counsel -
P. Terence Kohler,
Chief Financial Officer -
Matt Davidson,
10% owner -
John A Iii Stalfort,
Director -
Glenn A Oclassen,
Director -
Advisors Llcperceptive Life...,
-
Linda Palczuk,
Chief Operating Officer -
Chris Degnan,
Chief Financial Officer -
Terry Kohler,
CHIEF FINANCIAL OFFICER